Accropeutics’ Oral TYK2 Inhibitor AC-201 Cleared for Vitiligo Phase II/III
Accro Bioscience (Suzhou) Limited, better known as Accropeutics, announced on Sept 8, 2026 that its...
Accro Bioscience
Accro Bioscience Secures $50M Series C to Advance RIPK2 Inhibitor AC-101 into Phase IIb Ulcerative Colitis Trial
Accro Bioscience (Suzhou) Limited announced the completion of a $50 million Series C financing round,...
Accropeutics Doses First Patient in AC-101 Phase Ib UC Study
Accro Bioscience (Suzhou) limited, better known as Accropeutics, a clinical-stage biotech operating out of New...
Accropeutics Gets FDA Green Light for Phase II UC Study of RIPK2 Inhibitor AC-101
Accropeutics Inc., a clinical-stage biotechnology company with operations in New York, US, and Suzhou, China,...
Accropeutics Receives HREC Approval for AC-201 Phase I Trial
Suzhou-based Accro Bioscience (Suzhou) Limited (Accropeutics) has announced that it has received approval from the...